38
https://pubmed.ncbi.nlm.nih.gov/38116673
The experimental single-arm phase II clinical trial shows that neoadjuvant camrelizumab plus non-platinum-based chemotherapy has a promising pCR rate in early-stage TNBC, with an acceptable safety profile, and TAP1 and IRF4 may serve as potential predictive biomarkers for response to the NAT.